Agilent Technologies Obtains Multicolor, CGH Microarray Licenses from Abbott Molecular
PALO ALTO, Calif., Aug. 30, 2006 — Agilent Technologies Inc. (NYSE: A) today announced it has obtained worldwide, non-exclusive patent licenses from Abbott Molecular Inc. for the manufacture, marketing and sale of oligonucleotide microarrays using a two-or-more color technology for gene expression and comparative genomic hybridization (CGH) applications.
This broad license covers microarray applications, including research, commercial laboratories and in vitro diagnostics. Expressly built into the grant of rights are related products, instruments, components and services. Details of the licensing agreement were not disclosed.
“This intellectual property complements other recent Agilent investments in microarray fabrication technology and software,” said Nick Roelofs, vice president and general manager of Agilent’s Life Sciences Solutions Unit. “Our intent is to help researchers unlock the full potential of genomics.”